
EU health security planning prioritises protective equipment
Europe faces rising threats from pandemics, armed conflicts, chemical, biological and radiological exposure and nuclear (CBRN) attacks, and PPE is now viewed as critical not only for healthcare professionals, but also for care home staff, civil protection teams and humanitarian workers.
Commissioner for Equality, Preparedness and Crisis Management, Hadja Lahbib, said, 'We know the threats we face. And we know we can handle them. Hybrid attacks, power blackouts, extreme weather, and spreading diseases. These are no longer distant risks. That is why we are moving preparedness from the sidelines to the frontline of our defence.'
The Preparedness Strategy, adopted in March 2025, reflects this shift toward resilience, placing PPE on equal footing with vaccines and diagnostics. It also introduces preparedness roadmaps, a priority list of medical countermeasures, and sentinel systems like wastewater monitoring.
To support rapid deployment, the Commission is reinforcing its industrial base through EU FAB's ever-warm production and the new RAMP UP partnership.
From strategy to action
The Stockpiling Strategy establishes an EU network to coordinate reserves across Member States, improve visibility, reduce duplication, and guide joint recommendations.
In a statement to Euractiv, 3M welcomed stronger EU coordination on health preparedness.
'The two EU strategies underscore the critical importance of Personal Protective Equipment (PPE) in safeguarding frontline workers and the general population,' said Maxime Bureau, 3M Director of EU Government Affairs.
'The EU Stockpiling Network shows the EU's commitment to enhancing coordination among EU countries, ensuring transparency in the management and procurement of critical medical countermeasures, including PPE. As we move forward, it is essential to centralise actions at EU level to ensure a unified and efficient response to health emergencies, leveraging collective resources and expertise for the benefit of all Member States,' said Bureau.
The Commission expects this network to map national reserves, including their locations, contents and management, to improve coordination and crisis response.
Strengthening EU PPE reserves
As part of its wider preparedness push, the EU is expanding rescEU, originally created for wildfire response, to include pandemics and CBRN threats.
'One lesson learnt from the COVID-19 pandemic was the importance of developing and sustaining comprehensive medical stockpiles.'
These reserves now cover PPE, vaccines, medical devices and countermeasures for threats like zoonotic diseases and burns.
To improve sustainability, the EU is testing virtual stockpiling and vendor-based models to reduce waste and ensure access without constant replenishment.
In emergencies, rescEU allows direct or joint procurement and can cover up to 100% of transport costs.
Mobilising partnerships
The strategy also promotes public-private and civil-military partnerships to streamline logistics and supply chains. These collaborative models are seen as critical to delivering PPE and other stockpiled goods effectively during crises. This includes enhanced logistics and a fresh supply chain assessment for countermeasures not on the Union's critical medicines list, such as PPE or diagnostics.
'We will work with European companies in every Member State to make sure essential supplies, like food, water, medicines, masks, and testing kits, are ready when we need them,' said Commissioner Lahbib.
Driving innovation, preparedness
To improve readiness, HERA will continue to lead emergency procurement, manufacturing and R&D.
Its 2026 Medifence initiative aims to stockpile reusable PPE and support innovation in biosensors and drug platforms.
Meanwhile, the Medical Countermeasures Accelerator will help close innovation gaps in PPE, diagnostics, vaccines and treatments, offering regulatory and financial support.
HERA is also piloting a shelf-life extension scheme to reduce PPE waste.
Together, HERA and the Accelerator show the EU's broader shift from stockpiling alone to long-term innovation and preparedness.
The pandemic demonstrated the need for consistent funding. In response, the Commission has allocated over €5 billion from 2021–2027 via EU4Health, Horizon Europe and rescEU. Future funding will be debated during the next EU budget round.
MEP Nicolás González Casares warned that funding must match ambition.
'The truth is that the EU relies heavily on imports from China for much of its required PPE,' he said. 'While Horizon Europe and EU4Health can support R&D for more sustainable and scalable PPE, there should be European-specific funds for these needs. Otherwise, we risk diverting investment away from medical needs that are no less important.'
He called for financial tools to ensure both rapid response and long-term security.
'We have been discussing how to reinforce Europe's security strategy. Let's allocate targeted funds for the short-term and long-term reinforcement of strategic supply resources.'
Leaving no one behind
Equity is central to the EU's PPE strategy. González Casares stressed that distribution must go beyond hospitals, saying: 'There are two levels at which this issue is addressed: one related to ordinary shortages and the other related to crisis management'
'Obviously, the supply strategy must address both needs, as well as distribution. Not only is direct healthcare at hospitals a need, but so are other things. Care homes, humanitarian actors, and civil protection teams must also be covered.'
This reflects the Commission's commitment to ensuring shared EU resources benefit all Member States.
Looking ahead, the success of both strategies will hinge on implementation.
Key milestones now include the operational launch of the EU Stockpiling Network, deployment of the Medical Countermeasures Accelerator, and upcoming initiatives like Medifence in 2026.
With funding discussions tied to the next Multiannual Financial Framework, the coming weeks will be crucial to ensure the EU's ambition for strategic autonomy and crisis resilience translates into concrete preparedness on the ground.
[Edited By Brian Maguire | Euractiv's Advocacy Lab ]
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Euractiv
4 days ago
- Euractiv
Ireland publishes National Drugs Strategy as ministers battle rising cocaine use
Dublin - Ireland's health ministers have released an independent evaluation of the country's National Drugs Strategy (NDS), 'Reducing Harm, Supporting Recovery 2017–2025', highlighting progress in harm reduction and international alignment, while also identifying areas for structural reform. The report, commissioned by the Department of Health and conducted by Grant Thornton, assesses the strategy across four key domains: impact, governance, performance, and coherence with international policy frameworks. It fulfils a commitment made in the Programme for Government and arrives as policymakers prepare to draft a successor strategy by the end of 2025. The evaluation finds that the NDS has made 'notable progress in advancing a health-led approach,' particularly through the expansion of harm reduction measures such as naloxone distribution, needle exchange programmes, and drug-checking services. On governance, the report cites the establishment of strategic implementation groups and enhanced interagency collaboration at the local level as key achievements. These developments, it notes, have enabled 'more responsive and context-sensitive service delivery.' Performance metrics show improved data collection and monitoring. Shifting trends Cocaine emerged as the most common primary drug reported in treatment cases in 2024, underscoring a shift in Ireland's drug use profile. Ireland's latest drug use figures, published in 2025 by the Health Research Board, reveal a shifting landscape in substance use, with cannabis and cocaine remaining the most prevalent illicit drugs. Based on data from the 'Healthy Ireland Survey 2023', 7.8% of adults reported using cannabis in the past year, while cocaine use rose to 4.4%, particularly among those aged 25–34. Sedative and tranquilliser use stood at 2.5%, with higher rates among women and older adults. The report also highlights a rise in polydrug use and a strong correlation between drug use and other risk behaviours, including tobacco and alcohol consumption. EU drug strategy alignment Internationally, the strategy is deemed well-aligned with the EU Drugs Strategy and Action Plan 2021–2025, with Ireland's contributions to early warning systems and multilateral research initiatives receiving particular praise. However, the review also identifies persistent challenges, including fragmented delivery of prevention and early intervention services, and a need for alternatives to coercive sanctions. It outlines 10 strategic recommendations to guide the next phase of policy development. Minister for Health Jennifer Carroll MacNeill welcomed the report's focus on equity and access, noting alignment with ongoing Sláintecare reforms. 'The establishment of new HSE health regions presents a valuable opportunity to tailor drug treatment services to population needs and to ensure that both existing and new funding is allocated effectively and transparently,' she said. Carroll MacNeill also highlighted the importance of cross-border and EU collaboration: 'The upcoming Irish Presidency of the EU offers a unique opportunity to foster greater collaboration between member states, the EU Drugs Agency, and civil society organisations.' She added, 'Together, we can better address the health and preparedness challenges posed by an evolving and dynamic drugs market.' Minister for Public Health, Wellbeing and the National Drugs Strategy, Jennifer Murnane O'Connor reaffirmed her commitment to a health-led approach, including the proposed health diversion scheme. She welcomed 'the strong endorsement in the evaluation of the health-led response to drug use, including the proposed health diversion scheme for people found in possession of drugs for personal use. I am determined that the scheme will commence as soon as possible, in line with the commitments in the Programme for Government.' Next steps Murnane O'Connor announced the formation of a steering group to draft the next strategy. 'It is my ambition that the successor national drugs strategy will further strengthen the health-led approach to drug use by addressing the health and social needs of people who use drugs, reducing the harms for individuals, families and communities associated with drugs, and supporting recovery from drug addiction,' she said. The review's 10 recommendations include enhancing culturally sensitive services, increasing community engagement, aligning service delivery with regional needs, and investing in monitoring and research systems. It also calls for stronger integration of alcohol treatment services and continued development of alternatives to criminal sanctions. The evaluation follows the 2024 report of the Citizens' Assembly on Drug Use, which issued 36 recommendations spanning prevention, harm reduction, treatment, and recovery. These remain under active consideration by the Joint Oireachtas Committee on Drug Use and are expected to shape the forthcoming strategy. The EU Drugs Strategy 2021–2025 set out a robust, health-oriented framework to tackle drug-related issues across member states, balancing supply reduction with demand-side interventions. Central to the strategy has been harm reduction, international cooperation, and evidence-based policymaking, underpinned by commitments to human rights, gender equality, and public health. Its strategic goals have included enhancing security, expanding access to treatment, and reinforcing governance structures. The strategy also aligns with UN conventions and supports multilateral engagement. Its foremost priority is the disruption and dismantling of high-risk organised crime groups linked to drug trafficking, particularly those operating within or targeting the EU, and addressing their connections to broader security threats. By Brian Maguire


Euractiv
5 days ago
- Euractiv
A vaccine against cancer – but not for everyone
Some EU countries are beating HPV-related cancers, but others fail to provide life-saving measures. When Kim Hulscher sits upright at a table, her right leg swells. This is a lasting effect of lymphedema, a common cancer-related condition she developed after her cervical cancer treatment. 'I have to buy shoes that are twice my size because my foot won't fit into normal ones,' she says. Now, more than a decade after her diagnosis, she is speaking at the European Parliament during a conference titled 'Accelerating Progress Towards the EU's Goal of Eliminating HPV Cancers,' hosted by the European Cancer Organisation and the vice-chair of the Health Committee, Tilly Metz. Hulscher is there as co-chair of the European Society of Gynaecological Oncology – and as a cancer survivor committed to helping spare others what she went through. Hulscher's cervical cancer, like many others, was caused by a type of Human Papillomavirus (HPV), which can often be prevented through vaccination and detected early through screening. Far from elimination Yet Europe is still far from stopping these cancers. According to the World Health Organization, cervical cancer elimination means reducing incidence to fewer than four cases per 100,000 women. The most optimistic projections suggest that Europe could achieve this goal by 2050. In 2022, the ratio stood at 56 per 100,000 across the European Economic Area (EEA), which includes the EU, Iceland, Liechtenstein, and Norway. Around 130,000 women were newly diagnosed, and 14,000 died. HPV-linked head and neck cancers also remain significant causes of mortality. In 2022, 86,000 people were diagnosed, 74% of them men. These cancers caused about 26,000 deaths across the region. Vaccination at a young age is the most effective way to prevent such deaths. Once sexually active, HPV infection is nearly unavoidable. 'It is as contagious as a cold,' said Hulscher. Another participant put it more vividly: 'HPV is like glitter – it gets everywhere: in your car, in your pockets. So it doesn't have to be penetrative sex to catch it.' Often, HPV infections clear up on their own without causing lasting damage, and only about a dozen of the over 200 known HPV types are cancer-causing. However, the only sure way to avoid infection with these is to live like a nun or a monk. Last year, the European Council adopted recommendations urging countries to fully vaccinate at least 90% of girls and significantly increase uptake among boys. All EU member states now offer gender-neutral vaccination. Only five EEA countries – Portugal, Sweden, Cyprus, Iceland, and Norway – have reached the 90% coverage target for girls. 'There is a lot of work to be done,' said Karam Adel, principal expert at the European Centre for Disease Prevention and Control. He also noted a 'huge disparity between West and East,' with some countries reporting female coverage well below 50%. The price of inaction According to conference participants, vaccine scepticism, limited registries, and underfunded national vaccination programmes remain major roadblocks. The benefits of prevention, however, are not only medical but also financial. In a study involving six European countries (Romania, Poland, France, Austria, the Netherlands, and Germany), Maarten J. Postma, professor of medical sciences and an expert in health economics, estimated potential savings of €2.75 billion between 2030 and 2060. All it would take is for these countries to reach the 90% HPV vaccination target by 2030, along with WHO-recommended screening and treatment goals. 'We should conceive vaccination – and prevention in general – not as a cost but rather as an investment,' said Postma. Still, awareness remains low. "Consistently, studies show that whether it's children, young adults, or parents, people are unaware of the consequences of HPV infections," said Adel. He also stressed the importance of ongoing screening, even for those who are vaccinated, as vaccines do not cover all high-risk HPV types. Metz echoed the call for stronger education. "To truly eliminate HPV, we need progressive, inclusive, and scientifically accurate education – because empowering young people with knowledge is one of the most effective forms of prevention," she said. (de)


Euractiv
6 days ago
- Euractiv
Wild Animals Not Pets – The Case for an EU Positive List
Health This video captures highlights from the event: Wild Animals Not Pets – The Case for an EU Positive List. A gathering of policymakers, experts, and animal welfare advocates at the European Parliament to discuss the trade in wild animals and its implications for welfare, health, and biodiversity | 22 Jul 2025 | 12:00 | 1 min. read | video This video captures highlights from the event: Wild Animals Not Pets – The Case for an EU Positive List. A gathering of policymakers, experts, and animal welfare advocates at the European Parliament to discuss the trade in wild animals and its implications for welfare, health, and biodiversity. Speakers reflected on the importance of: Establishing an EU-wide positive list of species permitted as pets Addressing the risks wild animal trade poses to animal welfare, public health, and biodiversity Tackling fragmented national rules and the need for harmonised EU legislation Strengthening EU animal welfare frameworks to better protect wild species At a time when animal welfare and biodiversity face increasing pressures, these insights point to the need for coherent, science-based policies that safeguard both animals and society. Euractiv is part of the Trust Project More from this section